Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin
Open Access
- 7 June 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetologia
- Vol. 57 (9), 1869-1875
- https://doi.org/10.1007/s00125-014-3276-y
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Twelve type 2 diabetes susceptibility loci identified through large-scale association analysisNature Genetics, 2010
- New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes riskNature Genetics, 2010
- The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy menDiabetologia, 2009
- Association between TCF7L2gene polymorphisms and susceptibility to Type 2 Diabetes Mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysisBMC Medical Genetics, 2009
- Genome–wide association studies provide new insights into type 2 diabetes aetiologyNature Reviews Genetics, 2007
- Variation in TCF7L2 Influences Therapeutic Response to SulfonylureasDiabetes, 2007
- Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetesJCI Insight, 2007
- TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-analysisJournal of Molecular Medicine, 2007
- Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolutionNature Genetics, 2007
- Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetesNature Genetics, 2006